GSK To Pay $22M To End Diabetic Drug Marketing Row
GlaxoSmithKline LLC has agreed to pay $22 million to settle allegations that the company engaged in an illegal marketing campaign to promote diabetic drugs Avandia, Avandamet and Avandaryl, West Virginia Attorney...To view the full article, register now.
Already a subscriber? Click here to view full article